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We report a case of an iris tumor with mutton-fat keratic precipitates in a young patient after liver
transplantation surgery. A 6-year-old girl underwent liver transplantation for congenital biliary atresia
and was subsequently immunosuppressed with oral cyclosporine. We examined her 5 years after
transplantation because of a “white nodule in her left eye,” which had been detected by her father one
day before visiting our clinic. Ophthalmological examinations revealed symmetric visual acuity and
normal afferent papillary reﬂex. Slit-lamp examination revealed a depigmented iris nodule approxi-
mately3  2 mm with mutton-fat keratic precipitates in the anterior chamber. Fundus examination was
unremarkable, and computed tomography (CT) of the head, neck, and abdomen showed normal ﬁndings.
Based on the suspicion of post-transplant lymphoproliferative disorder (PTLD), therapy was initiated,
which included tapering cyclosporine and topical mydriatics. After 2.5 months, the lesion resolved and
no more mutton-fat keratic precipitates were identiﬁed in the anterior chamber. In this PTLD case, the
patient presented with an iris nodule and mutton-fat keratic precipitates, and the ocular PTLD presen-
tation resolved spontaneously after tapering cyclosporine.
Copyright © 2014, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Post-transplant lymphoproliferative disorders (PTLDs) are a
spectrum of diseases caused by lymphoplasmacytic proliferations
that occur as a result of immunosuppression following solid organ
or allogeneic hematopoietic cell transplantation.1 The spectrum of
PTLDs ranges from polymorphic, polyclonal proliferations with
features of viral infection, to monomorphic, monoclonal pro-
liferations, usually of the B-cell type.2 Primary ocular PTLDs
represent a distinct, late-onset, polyclonal lymphoproliferation
primarily affecting pediatric transplant patients.3 The uveal tract
becomes inﬁltrated by a mixture of lymphocytes and plasma cells,
and is often associated with the presence of Epstein-Barr virus
(EBV).4 In this case report, we present a patient who underwent
liver transplantation and subsequently developed presumed ocular
PTLD complications, which resolved after adjusting immunosup-
pression therapy.he authors declare that there
logy, Kaohsiung Chang Gung
of Medicine, 123 Dapi Road,
uo).
ciety of Taiwan. Published by Else2. Case Report
A 6-year-old girl underwent liver transplantation for congenital
biliary atresia and was placed on immunosuppression therapy with
oral cyclosporine (30 mg/day), with a mean cyclosporine level of
524 ng/mL in her blood during the 5th post-transplant year. Five
years after liver transplantation, she presented with a “white
nodule in her left eye”, which had been detected by her father the
day before attending our clinic. There was no previous history of
traumatic injury to the eye, and she denied any systemic discom-
fort. Visual acuity was 20/50 in both eyes, eye movements were full
and free and intraocular pressures were within normal limits. The
patient had normal light reﬂex in both eyes, but the examination of
the anterior segment revealed a highly vascularized, hypo-
pigmented iris nodule situated on the peripheral iris in her left eye
(Fig. 1). Multiple mutton-fat keratic precipitates were noted, but
there were no cells in the anterior chamber (standardization of
uveitis nomenclature, SUN grade 0). The vitreous cavity was clear
with no other mass lesions detected on B-scan ultrasonography or
dilated fundus examination. Examination of the right eye was un-
remarkable. Physical examination and systemic surveys including
computed tomography (CT) of the head, neck, chest, and abdomen
were performed and were within normal limits. Laboratory inves-
tigation of the patient's blood was positive for EBV DNA, Epstein-
Barr nuclear antigen-antibody (EBNA-Ab) (>1.640), and EB-Viralvier Taiwan LLC. All rights reserved.
Fig. 1. Hypopigmented neoplasm located between 7:00 and 8:00. Multiple mutton-fat
keratic precipitates noted.
Fig. 2. Resolved iris neoplasm and clear anterior chamber. Mutton-fat keratic pre-
cipitates have almost disappeared.
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negative for EB-Viral Capsid Antigen IgM antibody (EB-VCAM).
On suspicion of ocular PTLD without systemic involvement,
topical steroid and cycloplegic eye drops were given, along with the
adjustment of systemic cyclosporine dosage to 15 mg/day. Cyclo-
sporine levels in the blood and liver function tests were monitored
regularly. Six weeks after adjustment of the systemic cyclosporine
dosage, her blood cyclosporine levels dropped to 211 ng/mL, and
the iris nodule resolved spontaneously (Fig. 2). The patient is
currently maintained on oral cyclosporine 15 mg/day, without
additional immunosuppressive agents needed, and shows no signs
of graft rejection so far.
3. Discussion
Making a correct diagnosis is the essentialﬁrst step inmanaging a
pediatric patient with uveitis, which requires detailed history taking
thorough ophthalmic examination and selected laboratory tests.
Examination under general anesthesia may be needed in young pa-
tients should they be incapable of cooperating during the examina-
tion. For patients with suspected PTLD, differential diagnosis that
needed to be ruled out include, iris melanoma, retinoblastoma, ju-
venile xanthogranuloma, and intraocular foreign bodies.1,5
PTLDs are characterized by an uncontrolled proliferation of B-
cells as a result of immunosuppression following solid organ or
allogeneic hematopoietic cell transplantation. Immunosuppressive
therapy inhibits T-cell function, which leads to a reduction in B-cellgrowth suppression. Diagnosis of PTLD is based on both clinical and
histological criteria. Children were considered to have clinical evi-
dence suggestive of PTLD when there was evidence of lymphade-
nopathy, tonsillar hypertrophy, or extranodal masses on physical
examination.6 In ocular PTLD, a mixture of lymphocytes and plasma
cells diffusely inﬁltrates the uveal tissue. Cho et al7 reported that
anterior uveitis and iris nodules are the most common ocular
manifestations of PTLDs, but the posterior segment can also be
involved.
In young patients who have received organ or bone marrow
transplantation, it is reported that the 1-year post-transplantation
ocular complication rate is 16% (including cataract, keratoconjuncti-
vitis sicca secondary to Graft-versus-host-disease (GVHD), cyto-
megalovirus retinitis, PTLD, strabismus, transient visual loss,
preseptal cellulitis, allergic periorbital edema, and conjunctivitis) in
USA,4 whereas PTLDs occurs in 3% of all liver transplantation re-
cipients.4 The prevalence of PTLD in adult patients following liver
transplantation was reported to be 1.1% in a separate study.8 The
incidence of PTLD is signiﬁcantly higher in children (9.7%) than in
adults (2.9%), with an overall average incidence of 4.3%.9 Persistent
monoclonal immunoglobulins in liver transplantation recipients was
also associated with a 23% incidence of PTLD.10 The average time in-
terval between transplantation to PTLDs diagnosis is 50monthswith
a rangeof 5e140months.8 Inourpatient, a 6-year-oldgirl, the interval
between transplantation and PTLD diagnosis was 60 months.
Themajority of PTLD cases are associatedwith EBV infection.11,12
EBV induces uncontrolled proliferation of B-cells, which are nor-
mally regulated by cytotoxic T-cells and natural killer cells.11
Treatments for PTLD include prophylactic high-titer anti-EBV
intravenous immunoglobulin13 in high-risk (donor was EBV posi-
tive, recipient was EBV negative) pediatric recipients, intravenous
ganciclovir in high-risk EBV-positive donors to EBV-negative re-
cipients,14 and immunosuppressive therapy reduction.7 In previous
studies, EBV monitoring has been shown to be useful in high-risk
transplant recipients.6 In the study by Ho cyclosporine was
reduced to one-half of the original dosages after PTLD was diag-
nosed.15 In our patient, tapering the dosage of cyclosporine (from
30 mg/day to 15 mg/day) led to the resolution of the iris nodule
presumed to be due to PTLD.
Our patient's laboratory test for EB-VCAG was positive, but the
EB-VCAM was negative, indicating that she had a history of EBV
infection, but the infectionwas not in the acute phase. Parker et al16
suggested that patients must be monitored for EBV seroconversion
at the initial presentation of PTLD and then monthly (IgM to IgG
against VCAs) until the stable appearance of IgG EBNA-1. If the
lymph node or tonsillar enlargement does not improve, or worsens,
a biopsy should be performed. In our patient, EBV seroconversion to
IgG was present in the beginning of her clinical course. For the
evaluation of PTLD, Dhillon et al8 reported an investigation protocol
which included biopsy of the tumor/lymph nodemass for histology,
CT scans for staging (head, neck, chest, and abdomen), and analysis
of peripheral blood (full blood count, ﬂow cytometry for mono-
clonal B cells, EBV serology, and EBV load).
In the present case, the patient showed no signs of systemic
involvement and neurological symptoms. Because of the young age
of this patient and the family's concerns regarding the risk of general
anesthesia and complications of biopsy, including infection,
bleeding, and loss of vision, biopsy of the iris nodule was not per-
formed. However, our patient was followed up closely, with pro-
gressive regression of the iris tumor noted after reduction of
cyclosporine levels, andcomplete resolutionof the tumorby6weeks.
Nevertheless, inapatientwithmass lesionsor lymphadenopathydue
to suspected PTLD, where no documented improvements have been
noted after the reduction of immunosuppressive therapy, a low
threshold for biopsy is warranted to conﬁrm diagnosis.
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adults, and the majority of cases appear to be related to the pres-
ence of EBV. In our case, the diagnosis of PTLD was made based on
her history after having had a liver transplantation, the presence of
past EBV infection, and the regression of the iris tumor after
adjusting the immunosuppressant dose. When a patient is sus-
pected of having PTLDs, adjunctive evaluations may include staging
with CT of major organs, bone marrow aspiration, and peripheral
blood measurements and analysis including titers for EBV anti-
bodies. The patients should undergo frequent and careful moni-
toring, and biopsy of the tumor lesionwhenever possible to provide
a deﬁnite pathological diagnosis.References
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